Satisfactory remission achieved by PUVA therapy in a case of crisis-type adult T-cell leukaemia/lymphoma with generalized cutaneous leukaemic cell infiltration

Takemori, Nobuo; Hirai, Katsuyuki; Onodera, Ryuichi; Saito, Nagahito; Yokota, Kinichi; Kinouchi, Motoshi; Takahashi, Hiroyuki; Iizuka, Hajime

doi:10.1111/j.1365-2133.1995.tb06933.x

Cited by 16 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we have reported that PlNA therapy induces satisfactory remission in a crisis type adult T cell leukemia/lymphoma, suggesting that the treatment might be effective for cases with PlNA-susceptible cells not restricted to the skin (13). In other words, PlNA therapy could be effective in treating more or less systemically-involved cases of T cell malignancy (and activated Langerhans cells) by abrogating epidermotropic skin-associated PlNA-susceptible cells.…”

Section: Discussionmentioning

confidence: 99%

Satisfactory Remission Achieved by PUVA Therapy in Langerhans Cell Hisiocytosis in an Elderly Patient

Sakai¹,

Ibe²,

Takahashi³

et al. 1996

The Journal of Dermatology

View full text Add to dashboard Cite

Langerhans cell histiocytosis is currently regarded as a reactive proliferative process of Langerhans cells rather than a malignancy. The disease is characterized by Langerhans cell infiltration of skin, lung, bone and other organs. We report a 74-year-old man with Langerhans cell histiocytosis who had generalized hemorrhagic and crusted papules. He also had diabetes insipidus. Because he did not have any severe constitutional symptoms or failure of vital organs, we applied topical PUVA treatment to his skin lesions, which responded well to the therapy. Diabetes insipidus, however, remained, in spite of X ray radiotherapy for the pituitary lesion.

show abstract

Section: Discussionmentioning

confidence: 99%

Satisfactory Remission Achieved by PUVA Therapy in Langerhans Cell Hisiocytosis in an Elderly Patient

Sakai¹,

Ibe²,

Takahashi³

et al. 1996

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Interferon is apparently more effective for cutaneous lesions than for other lesions. 10,11 Psoralen plus ultraviolet A (PUVA) therapy 12 has been reported by dermatologist to be effective against generalized eruptions. Electron beam irradiation is also effective for a solitary skin nodules.…”

Section: Smoldering and Favorable Chronic Typesmentioning

confidence: 99%

Treatment of Adult T-cell Leukemia

Uozumi

2010

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Adult T-cell Leukemia (ATL) is an aggressive malignant disease of CD4 + T-cells associated with human T-cell leukemia virus type I (HTLV-I). Prognosis of ATL patients is directly correlated to the subtype of ATL. Treatment of the aggressive forms (acute and lymphoma types) of ATL remains inadequate, as most ATL patients receive conventional chemotherapy without stem cell rescue. At present, LSG15 is the standard chemotherapy for the treatment of aggressive ATL, but the efficacy of LSG15 in most patients is transient. To prolong median survival time, additional therapies for maintenance of complete response (CR) are needed after achieving CR by induction chemotherapy. Improved outcome after allogeneic stem cell transplantation (allo-SCT), despite a high incidence of graft-versus-host disease, has been reported. Thus, allogeneic bone marrow transplantation and allogeneic peripheral blood SCT may have great potential for eradication of HTLV-1 and cure of ATL. Recently, reduced-intensity conditioning stem cell transplantation was also reported to be effective for ATL. Although several issues, including selection criteria for patients and sources of stem cells remain to be resolved, allo-SCT may be considered as a treatment option for patients with aggressive ATL. To evaluate whether allo-SCT is more effective than the standard chemotherapy (LSG15) for aggressive ATL, an upfront phase II clinical trial of JCOG-LSG is now being planned. Novel innovative targeted strategies, such as antiretroviral therapy, arsenic trioxide, nuclear factor-kB inhibitors, proteasome inhibitors, histone deacetylase inhibitors, several monoclonal antibodies including anti-CC chemokine receptor 4, anti-folate, purine nucleotide phosphorylase inhibitor, mTOR (mammalian target of rapamycin) inhibitor, bendamustine, small molecule Bcl-2 inhibitors and Tax-targeted immunotherapy, should be promptly studied in order to develop curative treatments for ATL in the near future. 〔J Clin Exp Hematopathol 50(1) : 9-25, 2010〕

show abstract

“…In these forms, NB-UVB phototherapy is used for more superficial lesions and PUVA for more infiltrated lesions, with good results. 57,58 A recent study of patients with the smoldering form of ATL and cutaneous involvement demonstrated better survival in those treated with phototherapy combined with etoposide (25 to 75 mg/day for 2 to 4 weeks with a one-week interval or on alternate weeks). 35 As such, the favorable chronic and smoldering types of ATL are considered less aggressive and should be kept under observation until possible progression of the disease, similar to management of chronic lymphocytic leukemia and smoldering myeloma.…”

Section: Treatmentmentioning

confidence: 99%